Police & Firemen s Retirement System of New Jersey Makes New $80,000 Investment in Emergent Biosolutions Inc. $EBS

Police & Firemen s Retirement System of New Jersey purchased a new position in shares of Emergent Biosolutions Inc. (NYSE:EBS) in the second quarter, Holdings Channel.com reports. The firm purchased 12,538 shares of the biopharmaceutical company’s stock, valued at approximately $80,000.

Several other institutional investors have also made changes to their positions in EBS. Geode Capital Management LLC increased its holdings in Emergent Biosolutions by 108.9% in the second quarter. Geode Capital Management LLC now owns 1,278,998 shares of the biopharmaceutical company’s stock worth $8,162,000 after buying an additional 666,708 shares during the last quarter. Advyzon Investment Management LLC bought a new stake in Emergent Biosolutions in the second quarter worth approximately $90,000. ProShare Advisors LLC bought a new stake in Emergent Biosolutions in the second quarter worth approximately $71,000. Prescott Group Capital Management L.L.C. increased its stake in shares of Emergent Biosolutions by 23.1% during the 2nd quarter. Prescott Group Capital Management L.L.C. now owns 772,771 shares of the biopharmaceutical company’s stock worth $4,930,000 after purchasing an additional 145,100 shares during the last quarter. Finally, Acadian Asset Management LLC raised its holdings in shares of Emergent Biosolutions by 17.0% during the 2nd quarter. Acadian Asset Management LLC now owns 974,590 shares of the biopharmaceutical company’s stock valued at $6,216,000 after purchasing an additional 141,274 shares in the last quarter. 78.40% of the stock is currently owned by institutional investors and hedge funds.

Emergent Biosolutions Stock Up 1.1%

EBS stock opened at $11.17 on Friday. The stock has a market capitalization of $586.65 million, a price-to-earnings ratio of 8.59 and a beta of 2.06. The company has a 50-day moving average of $9.85 and a two-hundred day moving average of $8.14. Emergent Biosolutions Inc. has a 52-week low of $4.02 and a 52-week high of $13.41. The company has a debt-to-equity ratio of 1.25, a current ratio of 5.66 and a quick ratio of 3.00.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings data on Tuesday, January 9th. The biopharmaceutical company reported ($1.27) earnings per share for the quarter. Emergent Biosolutions had a return on equity of 21.43% and a net margin of 9.62%.The business had revenue of $222.50 million for the quarter. Emergent Biosolutions has set its FY 2023 guidance at EPS. As a group, equities research analysts anticipate that Emergent Biosolutions Inc. will post -0.63 EPS for the current year.

Insider Buying and Selling at Emergent Biosolutions

In other news, EVP Coleen Glessner sold 30,608 shares of the firm’s stock in a transaction on Tuesday, October 7th. The shares were sold at an average price of $10.00, for a total value of $306,080.00. Following the sale, the executive vice president owned 144,319 shares in the company, valued at approximately $1,443,190. This trade represents a 17.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.20% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on EBS shares. HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of Emergent Biosolutions in a report on Wednesday, September 3rd. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Emergent Biosolutions in a research report on Tuesday. Zacks Research upgraded Emergent Biosolutions to a “hold” rating in a research note on Friday, October 24th. Finally, Wall Street Zen raised Emergent Biosolutions from a “buy” rating to a “strong-buy” rating in a research note on Sunday. One analyst has rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $15.00.

About Emergent Biosolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.